tucatinib Feb 22, 2021 Seagen's Tukysa Combination Garners UK Approval for Advanced HER2-Positive Breast Cancer Dec 11, 2020 EMA Committee Recommends Approval for Seagen's Tukysa in Advanced HER2-Positive Breast Cancer Sep 14, 2020 Merck Invests $1B, Pays $725M Upfront for Two Seattle Genetics Precision Oncology Drugs Breaking News California Governor Vetoes Biomarker Test Coverage Bill Massive Bio, Perthera Partner on Biomarker-Based Clinical Trial Matching Autolus Therapeutics, BMS Partner to Develop Cell Therapies Equipped With Safety Switches Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Seneca Therapeutics Cleared by FDA to Start Phase I/II Oncolytic Virus Trial
